PL1776336T3 - Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne - Google Patents

Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne

Info

Publication number
PL1776336T3
PL1776336T3 PL05729779T PL05729779T PL1776336T3 PL 1776336 T3 PL1776336 T3 PL 1776336T3 PL 05729779 T PL05729779 T PL 05729779T PL 05729779 T PL05729779 T PL 05729779T PL 1776336 T3 PL1776336 T3 PL 1776336T3
Authority
PL
Poland
Prior art keywords
treatment
acid derivatives
prevention
compounds
pharmaceutical compositions
Prior art date
Application number
PL05729779T
Other languages
English (en)
Inventor
Marcello Allegretti
Riccardo Bertini
Maria Candida Cesta
Marco Mosca
Francesco Colotta
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of PL1776336T3 publication Critical patent/PL1776336T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL05729779T 2004-03-23 2005-03-21 Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne PL1776336T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04101202 2004-03-23
EP05729779A EP1776336B1 (en) 2004-03-23 2005-03-21 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them
PCT/EP2005/051302 WO2005090295A2 (en) 2004-03-23 2005-03-21 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
PL1776336T3 true PL1776336T3 (pl) 2010-06-30

Family

ID=34970877

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05729779T PL1776336T3 (pl) 2004-03-23 2005-03-21 Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne

Country Status (20)

Country Link
US (2) US8039656B2 (pl)
EP (1) EP1776336B1 (pl)
JP (1) JP4871257B2 (pl)
CN (2) CN1934077B (pl)
AT (1) ATE444286T1 (pl)
AU (1) AU2005223402B2 (pl)
CA (1) CA2553705C (pl)
CY (1) CY1109687T1 (pl)
DE (1) DE602005016937D1 (pl)
DK (1) DK1776336T3 (pl)
ES (1) ES2333445T3 (pl)
HR (1) HRP20090681T1 (pl)
ME (1) ME01763B (pl)
NO (1) NO337685B1 (pl)
PL (1) PL1776336T3 (pl)
PT (1) PT1776336E (pl)
RS (1) RS51109B (pl)
RU (1) RU2375347C2 (pl)
SI (1) SI1776336T1 (pl)
WO (1) WO2005090295A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629935C (en) 2005-11-24 2016-01-19 Dompe S.P.A. (r)-arylalkylamino derivatives and pharmaceutical compositions containing them
PT2024329E (pt) * 2006-05-18 2013-11-04 Dompe Spa (2r)-2-[(4-sulfonil)aminofenil]propanamidas e composições farmacêuticas que as contenham
EP2094638B1 (en) 2006-12-19 2012-08-08 Dompe' S.P.A. 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2316820A1 (en) * 2009-10-28 2011-05-04 Dompe S.p.A. 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3117835A1 (en) * 2015-07-14 2017-01-18 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment of certain urological disorders
WO2017121838A1 (en) 2016-01-15 2017-07-20 Dompe' Farmaceutici S.P.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP3192504A1 (en) 2016-01-15 2017-07-19 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
WO2018067548A1 (en) 2016-10-03 2018-04-12 The Children's Medicial Center Corporation Prevention and treatment of diabetic nephropathy
EP3342407A1 (en) 2017-01-03 2018-07-04 Dompé farmaceutici S.p.A. Il-8 inihibitors for use in the treatment of some urological disorders
EP3409277A1 (en) 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
EP3476390A1 (en) * 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
EP3868368A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof
EP3868369A1 (en) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
EP3884932A1 (en) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
WO2021191305A1 (en) 2020-03-26 2021-09-30 Dompe' Farmaceutici Spa Cxcl8 inhibitors for use in the treatment of covid-19
EP4008325A1 (en) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
US20240115527A1 (en) * 2020-11-05 2024-04-11 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (en) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
KR20230092100A (ko) * 2021-12-16 2023-06-26 주식회사 동진쎄미켐 염 화합물 및 이를 포함하는 산확산 억제제, 포토레지스트 조성물
EP4397305A1 (en) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid
EP4563594A1 (en) 2023-11-28 2025-06-04 Dompe' Farmaceutici SpA Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0964849B1 (en) * 1997-01-29 2003-06-04 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
ITMI20012025A1 (it) * 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
JP5208411B2 (ja) * 2003-02-06 2013-06-12 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ ２−アリール−酢酸、その誘導体、及びそれらを含有する医薬組成物
PT1663960E (pt) * 2003-09-25 2011-12-16 Dompe Spa Amidinas e os seus derivados e composições farmacêuticas que os contêm

Also Published As

Publication number Publication date
CN1934077A (zh) 2007-03-21
CN1934077B (zh) 2010-09-29
DK1776336T3 (da) 2010-01-18
SI1776336T1 (sl) 2010-01-29
ME01763B (me) 2010-10-31
JP2007530505A (ja) 2007-11-01
EP1776336A2 (en) 2007-04-25
DE602005016937D1 (de) 2009-11-12
CA2553705C (en) 2012-12-11
WO2005090295A3 (en) 2005-10-27
US8293788B2 (en) 2012-10-23
US8039656B2 (en) 2011-10-18
US20090203740A1 (en) 2009-08-13
NO337685B1 (no) 2016-06-06
HK1101392A1 (en) 2007-10-18
HK1148219A1 (en) 2011-09-02
CY1109687T1 (el) 2014-08-13
HRP20090681T1 (hr) 2010-02-28
JP4871257B2 (ja) 2012-02-08
CN101912382A (zh) 2010-12-15
NO20064766L (no) 2006-10-20
CN101912382B (zh) 2012-11-21
ATE444286T1 (de) 2009-10-15
ES2333445T3 (es) 2010-02-22
AU2005223402A1 (en) 2005-09-29
EP1776336B1 (en) 2009-09-30
AU2005223402B2 (en) 2011-07-21
US20120004264A1 (en) 2012-01-05
WO2005090295A2 (en) 2005-09-29
RU2006137272A (ru) 2008-04-27
RS51109B (sr) 2010-10-31
PT1776336E (pt) 2009-12-18
RU2375347C2 (ru) 2009-12-10
CA2553705A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
SI1776336T1 (sl) Derivati 2-fenilpropionske kisline in farmacevtski sestavki, ki jih vsebujejo
WO2004080951A3 (en) Sulfonic acids, their derivatives and pharmaceutical compositions containing them
Cocco et al. Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties
Schrøder et al. The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin
NO20074641L (no) 1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
TW200626142A (en) Chemical compounds
EA200701361A1 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
Gilbert et al. N-((8-Hydroxy-5-substituted-quinolin-7-yl)(phenyl) methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2)
WO2004069782A3 (en) 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them
BR0214322A (pt) ácidos 2-aril-propiÈnicos e composições farmacêuticas contendo os mesmos
George et al. Discovery of thieno [2, 3-c] pyridines as potent COT inhibitors
NO20080165L (no) Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister
Miller et al. Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas—the effect of capping the distal basic piperidine nitrogen
DE602006007210D1 (de) Metaboliten aus 2-arylpropionsäure-derivaten und pharmazeutische zusammensetzungen damit
YU62801A (sh) Derivati 4-heterociklilsulfonamidil-6-metoksi-5-(2-metoksi- fenoksi)-2-piridil- piridimina, njihovo dobivanje i primena kao antagonisti endotelinskih receptora
Yokokawa et al. Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000–2008
Wei et al. CCR5 receptor antagonists: Discovery and SAR study of guanylhydrazone derivatives
HRP20090489T1 (hr) Hidantoinski derivati korisni kao inhibitori metaloproteinaza
Laliberté et al. Discovery of a series of aryl-N-(3-(alkylamino)-5-(trifluoromethyl) phenyl) benzamides as TRPA1 antagonists
Walker et al. Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase
De Savi et al. Selective non zinc binding inhibitors of MMP13
NO20055752L (no) N-ureidoalkyl-piperidiner som modulerer forbindelser av kjemokinreseptor-aktivitet
Sutton et al. From virtual to clinical: the discovery of PGN-1531, a novel antagonist of the prostanoid EP4 receptor
Miller et al. Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl) phenyl) benzamides as muscarinic acetylcholine receptor subtype 1 (M1) anatgonists
Venkatraman et al. Influence of acid surrogates toward potency of VLA-4 antagonist